Diabetic Retinopathy Screening Using AI

Our DR screening solution enables primary care providers to screen patients in-clinic instead of referring to specialists

View Full Video

Book a Demo

AEYE Diagnostic Screening

AEYE Diagnostic Screening (AEYE-DS) utilizes Artificial Intelligence (AI) technology to diagnose diabetic retinopathy from retinal images.

First to be proven accurate on both a desktop camera and a portable handheld camera

AEYE with TOPCON

AEYE-DS software in use on a computer presenting the fundus images analyzed with the diabetic retinopathy diagnostic result

AURORA AEYE

CAUTION: Federal (US) law restricts this device to investigational use only.

NOT SOLD IN THE US

Best-in-class Accuracy

Proven accurate in a prospecitve clinical trial

Desktop

93.0%

Sensitivity

91.4%

Specificity

Handheld

93.6%

Specificity

91.9%

Sensitivity

Vector Images of desktop and a Portable fundus cameras

The Only Practical Solution

The exam takes under 2 minutes for most patients and rarely requires dilation

handheld & desktop

1 Image

Per eye

Imageability

>99%

Vector Art of a Feemale healthcare professional with a reimbursable report representing closing care gaps

Closes Care Gaps

Enables point-of-care screening instead of referring to a specialist

Reimbursement code

CPT 92229

HEDIS Quality Measure

Measure 117

Our Products

Over 35M

people with diabetes in the US and 422M worldwide are at risk of sight-threatening diabetic retinopathy.

85%

of people over 40 with diabetes will develop diabetic retinopathy.

Why it matters

Screening Prevents Blindness

Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.

Only 15% to 50%

of patients with diabetes in the US adhere to the recommended screening.

Closing care gaps

Replacing specialist screening with AI diagnosis

Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap

Before

After

The first image shows the current diabetic retinopathy screening process where by a patient receives an annual referral for an eye exam and less than 50% adhere to the screening. In the second image the solution is shown where by a patient receives on-the-spot diagnosis during a GP visit and is then either cleared for 12 months due to negative result or referred to a specialist for treatment if the result is positive.

Vector Art of Point of Care Screening Solution Process by AEYE Health. The image has Male Doctor photo detecting diabetic reinopathy and screening tool

Benefits of
Point-of-Care Screening

Practical

Requires only one image per eye; rarely requires dilation

Vector Art of Target Icon representing best in accuracy

Accurate

Best-in-class efficacy proven in a pivotal prospective FDA study

Simple to operate

Screening, taking only two minutes for most patients, can be done by any healthcare staff

Reimbursable

Dedicated CPT code 92229

Closes Care Gaps

Closes the diabetic eye exam care gap for HEDIS/Star quality measures

Our Mission

Autonomous comprehensive diagnostic screening for a broad range of diseases using retinal images

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in working-age adults in the US.

Our FDA-cleared technology enables accessible early detection, which can save the sight of millions.

Best-in-class accuracy

Published results

Glaucoma

Glaucoma is the second most common cause of blindness worldwide.

Our algorithm enables early detection and accessible screening, encouraging timely and effective treatment. Our results are also the first to show high agreement with eye doctors.

Best-in-class accuracy

Coming soon

Age-Related Macular Degeneration (AMD)

Age-related Macular Degeneration is an extremely common condition which impairs sharp central vision.

Our algorithm enables early detection, which can aid in dramatically slowing disease progression. Results for our best-in-class solution will be published imminently.